151. Pregnancy in adult‐onset dermatomyositis/polymyositis: A systematic review
- Author
-
Keyun, Tang, Jia, Zhou, Yining, Lan, Hanlin, Zhang, and Hongzhong, Jin
- Subjects
Adult ,Immunology ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,Dermatomyositis ,Polymyositis ,Reproductive Medicine ,Pregnancy ,Humans ,Premature Birth ,Immunology and Allergy ,Female ,Glucocorticoids - Abstract
Idiopathic inflammatory myopathy (IIM) in pregnancy is uncommon but may result in complications for both mother and the fetus.In this systematic review, we summarized the current literature investigating outcomes of pregnancy related to the dermatomyositis/polymyositis (DM/PM) process.We searched PubMed, Embase, Cochrane Library, and Web of Science databases and included 61 studies reporting the disease course, pregnancy outcomes, and management of both pregnancy and DM/PM in the final analysis.The specific information of 221 pregnancies was extracted and these pregnancies were divided into three distinct forms: pregnancies after disease onset (n = 159), pregnancies with new disease onset (n = 37), and pregnancies followed by postpartum onset (n = 25). In most cases, DM/PM disease activity remained stable or improved throughout pregnancy (80.2%) and the postpartum period (83.9%). Active DM/PM during pregnancy significantly increased the risk of stillbirth or neonatal death (12% vs. 1%, P = .005) and preterm birth (34.7% vs. 11%, P .001). The rates of other poor outcomes (total fetal loss, low birth weight, and intrauterine growth retardation) were also increased in pregnancies with active disease. Mainstay treatments for active DM/PM during pregnancy are glucocorticoids and intravenous immunoglobins.The present results underline the importance of good control of myopathy in optimizing the pregnancy outcomes of women with DM/PM.
- Published
- 2022